What is AGIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.90B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AGIO?

P/E (TTM) is n/a and 52-week range is $22.24 to $46.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AGIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AGIO?

The company profile lists revenue (TTM) near $98M, net income (TTM) near $-41.11B, EPS (TTM) near $-7.01 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Agios Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 59.5M shares outstanding, ISIN US00847X1046 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Agios Pharmaceuticals Inc

$AGIO

Health Care · Biotechnology

IR Run Scenarios

$31.81

-0.34%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 539 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.

Employees

539

Website

www.agios.com/

IPO

2013-07-24

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)